MacroGenics (NASDAQ:MGNX) PT Raised to $16.00 at JMP Securities

MacroGenics (NASDAQ:MGNX – Free Report) had its target price raised by JMP Securities from $10.00 to $16.00 in a report released on Wednesday, Benzinga reports. They currently have a market outperform rating on the biopharmaceutical company’s stock. Several other equities analysts have also recently issued reports on the company. StockNews.com cut MacroGenics from a buy […]

Related Keywords

United States ,Canada ,Stifel Nicolaus ,Ezio Bonvini ,Ensign Peak Advisors Inc ,Tower Research Capital ,Securities Exchange Commission ,Citigroup ,Royal Bank ,Macrogenics Inc ,Macrogenics Company Profile ,Free Report ,Moderate Buy ,Get Free Report ,Exchange Commission ,Research Capital ,Peak Advisors Inc ,Exoduspoint Capital Management ,Macrogenics Daily ,Macrogenics ,Nasdaq Mgnx ,Mgnx ,Medical ,Boost Price Target ,Jmp Securities ,